Question Everything. See who's reporting it.

Activists seek early decision on better access to life-saving breast cancer medicine

Source: The Hindu

The story in brief

After the original petitioner's death, the High Court continued the case suo motu, recognizing public interest. The working group, comprising patient advocates, legal experts, and healthcare professionals, urged action on life-saving breast cancer drugs like Ribociclib and Abemaciclib, costing ₹78,460.75 and ₹47,752–₹95,504 monthly. Generic versions, 90–95% cheaper, remain inaccessible due to patent protections.

4 outletsSee what the other 3 outlets said

NEWXFree on Android and iPhone. Open in NEWX